17 completed. 17 Phase 2, 1 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 17 | Completed 17 |
| Phase 1 | 1 | Completed 1 |
| Phase 3 | 1 | Completed 1 |
Follow Primary Open Angle Glaucoma: new trials by email Literature Review of Primary Open Angle Glaucoma trials Research Report on Primary Open Angle Glaucoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Ph2 Placebo-Controlled Study for Safety & Ocular Efficacy of SBI-100 Ophthalmic Emulsion in Pts w/ Elevated Eye Pressure SBI-100 Ophthalmic Emulsion, 0.5%, SBI-100 Ophthalmic Emulsion, 1.0%, SBI-100 Ophthalmic Emulsion, Placebo - Primary Open Angle Glaucoma, Ocular Hypertension | Phase 2 | Completed | Skye Bioscience, Inc. | 56 | 2023-11-09 | 2026-01-14 |
| Study to Evaluate QLS-101 Compared to Timolol Maleate Eye Drops in Subjects With High Eye Pressure (Glaucoma or Ocular Hypertension). QLS-101, Timolol Maleate - Primary Open Angle Glaucoma, Ocular Hypertension | Phase 2 | Completed | Qlaris Bio, Inc. | 84 | 2021-03-31 | 2025-01-17 |
| Study of LL-BMT1 in Patients With Elevated Intraocular Pressure LL-BMT1 - Primary Open Angle Glaucoma, Ocular Hypertension | Phase 2 | Completed | MediPrint Ophthalmics, Inc. | 5 | 2021-01-08 | 2022-06-08 |
| Multicenter Study Assessing the Efficacy and Safety of DE-126 Ophthalmic Solution 0.002% Compared With Timolol Maleate Ophthalmic Solution 0.5% in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension DE-126 Ophthalmic Solution 0.002% QD, Timolol Maleate Ophthalmic Solution 0.5% BID - Primary Open Angle Glaucoma, Ocular Hypertension | Phase 2 | Completed | Santen Inc. | 323 | 2020-12-17 | 2023-06-22 |
| Study to Assess the Efficacy, Safety and Tolerability of AKB-9778 Ophthalmic Solution as and Adjunct to Latanoprost in Patients With Ocular Hypertension or Open Angle Glaucoma Latanoprost ophthalmic solution, AKB-9778 4%, Placebo - Ocular Hypertension, Primary Open Angle Glaucoma | Phase 2 | Completed | EyePoint Pharmaceuticals, Inc. | 194 | 2020-06-06 | 2023-05-25 |
| Ahmed Glaucoma Valve Surgery With Mitomycin-C Mitomycin-C, Balanced Salt Solution, Ahmed Glaucoma Valve Implant - Glaucoma, Primary Open Angle Glaucoma | Phase 2 | Completed | University of California, San Francisco | 119 | 2016-06-01 | 2022-05-31 |
| A Study Assessing the Efficacy and Safety of DE-117 Ophthalmic Solution in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension -AYAME Study- Placebo ophthalmic solution, DE-117 ophthalmic solution low, DE-117 ophthalmic solution high - Primary Open Angle Glaucoma, Ocular Hypertension | Phase 2 / Phase 3 | Completed | Santen Pharmaceutical Co., Ltd. | 253 | 2015-12-06 | 2017-11-20 |
| The Effect of Sponge Versus No-Sponge Placement of Mitomycin-C on the Outcomes of Trabeculectomy With Ex-PRESS Glaucoma Filtration Device Placement of the sponge, Mitomycin-C - Primary Open Angle Glaucoma | Phase 2 | Completed | Duke University | 100 | 2014-03-01 | 2018-02-09 |
| Study to Compare the Safety and Efficacy of ALZ-1101 to Latanoprost in Patients With Intraocular Pressure Inadequately Controlled by Latanoprost ALZ-1101, Latanoprost - Primary Open Angle Glaucoma, Ocular Hypertension | Phase 2 | Completed | Alleanza Pharmaceuticals, Inc. | 63 | 2013-07-01 | 2014-09-30 |
| ATS907 Ph2a Open-Label Dose-ranging Safety and Tolerability in Primary Open Angle Glaucoma (POAG) and Ocular Hypertension (OHT) Subjects ATS907 - Primary Open Angle Glaucoma, Ocular Hypertension | Phase 2 | Completed | Altheos, Inc. | 12 | 2012-08-01 | 2012-09-07 |
| Transconjunctival Needling Revision Versus Medical Treatment Transconjunctival needling revision, Medical treatment - Primary Open Angle Glaucoma | Phase 2 | Completed | University of Sao Paulo General Hospital | 40 | 2010-05-01 | 2013-06-27 |
| Safety and Efficacy Study of the Hydrus Aqueous Implant in Subjects With POAG prestudy topical glaucoma medications - Primary Open Angle Glaucoma | Phase 1 / Phase 2 | Completed | Ivantis, Inc. | 120 | 2010-03-01 | 2019-02-04 |
| Pharmacokinetics, Efficacy and Safety Assessment of T2345 Compared With Active Comparator in Newly Diagnosed Patients With Open-angle Glaucoma or Ocular Hypertension T2345, Prostaglandin - Primary Open Angle Glaucoma | Phase 2 | Completed | Laboratoires Thea | 30 | 2008-06-01 | 2024-02-07 |
| A Phase 2, Dose Finding Study of PF-03187207 in Patients With Primary Open Angle Glaucoma or Ocular Hypertension. PF-03187207, Latanoprost 0.005%, PF-03187207 Vehicle - Primary Open Angle Glaucoma, Ocular Hypertension | Phase 2 | Completed | Bausch & Lomb Incorporated | 117 | 2007-12-01 | 2020-09-14 |
| Dose-Finding Study Comparing the Safety and Efficacy of Latanoprost to a Novel Treatment for Glaucoma PF-03187207 and Latanoprost Vehicle, Latanoprost 0.005% and PF-03187207 Vehicle - Primary Open Angle Glaucoma, Ocular Hypertension | Phase 2 | Completed | Bausch & Lomb Incorporated | 176 | 2007-03-01 | 2020-09-14 |
| Clinical Study of A Fixed Combination of Timolol-Brimonidine-Dorzolamide dorzolamide-timolol-brimonidine - Primary Open Angle Glaucoma, Ocular Hypertension | Phase 2 | Completed | Laboratorios Sophia S.A de C.V. | 124 | 2006-02-01 | 2019-08-01 |
| A Study Comparing The Efficacy, Safety And Tolerability Of Latanoprost 75, 100 And 125 ug/ml To Xalatan In The Treatment Of Primary Open-Angle Glaucoma And Ocular Hypertension latanoprost 75 ug, latanoprost 100 ug, latanoprost 125 ug - Primary Open Angle Glaucoma, Ocular Hypertension | Phase 2 | Completed | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | 282 | 2003-01-01 | 2021-02-02 |
Glaucoma, Open-Angle (17) · Ocular Hypertension (12) · Glaucoma (5) · Glaucoma, Neovascular (1)
Eye Diseases (17) · Glaucoma (12) · Ocular Hypertension (5)
Latanoprost (6) · Mitomycin (2) · BID protein, human (1) · Brimonidine Tartrate (1) · Hanks Balanced Salt Solution (1) · Prostaglandins (1) · Timolol (1) · dorzolamide (1) · dorzolamide-timolol combination (1)
Bausch & Lomb Incorporated (2) · Alleanza Pharmaceuticals, Inc. (1) · Altheos, Inc. (1) · Duke University (1) · EyePoint Pharmaceuticals, Inc. (1) · Ivantis, Inc. (1) · Laboratoires Thea (1) · Laboratorios Sophia S.A de C.V. (1) · MediPrint Ophthalmics, Inc. (1) · Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (1) · Qlaris Bio, Inc. (1) · Santen Inc. (1) · Santen Pharmaceutical Co., Ltd. (1) · Skye Bioscience, Inc. (1) · University of California, San Francisco (1)
United States (10) · Mexico (3) · Japan (2) · Australia (1) · Austria (1) · Brazil (1) · China (1) · Czechia (1) · France (1) · Germany (1) · Greece (1) · India (1) · Pakistan (1) · Portugal (1) · Thailand (1)
Ken Harper (1) · Kenneth Harper (1) · Leon Herndon, MD (1) · Leopoldo M Baiza-Duran, MD (1) · Prof. Dr. Manfred Tetz, MD (1) · Remo Susanna Jr., MD (1) · Ricardo Suzuki, MD (1) · Tu Diep (1) · Ying Han, MD, PhD (1)
PMID 22607109, PMID 24212847, PMID 27310103, PMID 29189540, PMID 32533949, PMID 40043909, PMID 9261306